Barclays’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Barclays’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-105	Closed	-$8K	–	4849
2021 Q3	$8K	Buy	105 +26	+33%	+$1.9K	﹤0.01%	4556
2021 Q2	$6K	Sell	79 -373	-83%	-$22.7K	﹤0.01%	4738
2021 Q1	$30K	Buy	+452	New	+$35.2K	﹤0.01%	4299
2019 Q4	–	Sell	-2	Closed	–	–	6940
2019 Q3	$0	Buy	+2	New	+$144	﹤0.01%	7244
2019 Q2	–	Sell	-2,465	Closed	-$364K	–	7373
2019 Q1	$364K	Buy	2,465 +1,769	+254%	+$342K	﹤0.01%	4365
2018 Q4	$110K	Buy	+696	New	+$133K	﹤0.01%	4984
2018 Q2	–	Sell	-24	Closed	-$6K	–	7378
2018 Q1	$6K	Sell	24 -1,491	-98%	-$391K	﹤0.01%	6766
2017 Q4	$466K	Buy	+1,515	New	+$498K	﹤0.01%	3906
2016 Q3	–	Sell	-41	Closed	-$8K	–	6853
2016 Q2	$8K	Buy	+41	New	+$18.9K	﹤0.01%	5624

Other funds holding DMK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays's DMK Position: Q4 2021 in Review

Barclays sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q4 2021, closing a stake of 105 shares — an estimated $8K sold.

Barclays first reported a position in DMK in Q2 2016 and held it in 9 quarters. The position peaked at $466K in Q4 2017. 49 funds tracked by Wall St. Rank hold DMK as of Q4 2021.

Barclays reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q4 2021 after selling out during the quarter.
Barclays sold 105 DMK Pharmaceuticals Corporation Common Stock shares in Q4 2021, an estimated $8K.
Barclays first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q2 2016 and held it in 9 quarters.
Barclays's DMK Pharmaceuticals Corporation Common Stock position peaked at $466K in Q4 2017.
49 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.